According to a report published by the American Society of Plastic Surgeons not only does the demand for Injectables (dermal fillers and Botox) continue to grow, but the expansion of new formulas is evolving too. New neurotoxins (similar to Botox) will last remarkably longer and fillers (similar to Juvederm) are expected to be offering exciting new cutting-edge non surgical technologies.
Defy Nature learned from experts about what makes these products different from the others and why we are so excited to offer them in the near future.
Daxibotulinum toxin (or DAXI) by Revance
DAXI, a new botulinum A toxin for glabellar wrinkles (frown lines between the forehead), was developed by Revance that’s anticipated to launch following a U.S. FDA approval. This new wrinkle reducer is expected to be available in the latter part of this year. What’s new about this product is that studies have indicated the duration or time is will last is longer than that of the current market botulinum toxin (like Botox). DAXI has a proprietary peptide that differs from our currently available botulinum type A toxins.
Bonti botulinum toxin by Allergan
Bonti is the new toxin being developed by Allergan. This product should have an extremely quick onset of action [within 24 hours] rather than Botox which takes usually 3-5 days. Bonti will have a shorter effect, lasting two to four weeks. But it will be a great option for first-timers wanting to try out a treatment and can also help people who need a last-minute touch-up before a big event.
Available only in Europe and Canada, Juvéderm Volite is not a dermal filler but rather an injectable treatment intended to improve skin quality for up to nine months. Volite contains skin-conditioning hyaluronic acid (HA) gel, to help reduce the appearance of fine lines while also helping the overall tone and texture of the skin itself. The main goal for this treatment is to help make the face look more hydrated rather than diminish the appearance of wrinkles or add volume to the face. Not only is Volite used to hydrate the skin thanks to HA’s high water-binding capacity, but it also helps increase overall elasticity too. 2021 is when this product is expect to hit the U.S. market.
Juvéderm Volux is another hyaluronic acid (HA)-based dermal filler designed to replace lost facial volume. Volux is denser than many fillers on the market—it’s made to mimic bone—and creates a more lifted look. Because the consistency of the product is so dense, it’s often used in the jawline and chin area, to sculpt the area. Volux isn’t available in the U.S. just yet, and like Juvéderm Volite, most likely be available until 2021.
Restylane Kysse by Galderma
Officially approved by the FDA in April 2020, Restylane Kysse is a new hyaluronic acid filler developed by Galderma that is indicated for the lips and surrounding wrinkles. It incorporates similar technology as Restylane Silk, but offers better flexibility in the skin to allow for more natural lip movement. The cross-linking of the hyaluronic acid gel in Kysse has also been specifically developed to minimize swelling while producing results for up to a year. Restylane Silk, gives a plumper pout for up to six months and Kysse was shown to give long-lasting results for up to one year.